Johnson & Johnson announces new data from Tremfya phase 3 QUASAR LTE study in adults with moderately─to─severely active ...
Johnson & Johnson announced new data from the Tremfya (guselkumab) phase 3 QUASAR long-term extension (LTE) study in adults with moderately-to-severely active ulcerative colitis (UC). These data are among 24 abstracts highlighting the company’s …